488.97 20.70% 237.45 10.45% Short-term investment 4.85 0.21% 21.35 0.94% Account receivable, trade and others 706.03 29.89% 679.83 29.93% Inventories 663.32 28.08% 792.71 34.90% Other current assets 3.24
Assets The total asset as at December 31, 2019 was decreased in an amounting of Baht 182.30 million or 19.09 percent from year end 2018. Significant changes was included Trade and other receivable was
–19 Q1–20 VS Q4–19 (MB) (MB) % Cash and cash equivalent 357.1 190.2 166.9 87.7% Trade and other receivables 2,512.5 2,268.6 243.9 10.8% Inventories 1,244.8 745.9 498.9 66.9% Advance payment for products
losses as financial assets. The Company will measure fair value of all derivatives and recognised in profit and loss statement, while the credit losses is to consider as impairment of trade receivables
that has significant changes Balance by Quarter Change Q2–21 Q4–20 Q2–21 VS Q4–20 (MB) (MB) % Cash and cash equivalent 166.2 204.5 (38.3) (18.7) Trade and other receivables 3,729.8 2,633.9 1,095.9 41.6
Type 2 Transaction (List 1). DOD Biotech Public Company Limited (the “Company”) hereby notifies the significant resolutions passed by the Board of Directors’ Meeting No. 8/2018, held on December 19, 2018
rating (if any); (6) any other information related to the trading of debt securities or having similar characteristics or related to the information under (1), (2), (3), (4) and (5). “REIT manager” means a
กองทุน CIS ต่างประเทศ concentration limit อัตราส่วนการลงทุนที่คำนวณตามความมีส่วนได้เสียในกิจการท่ีลงทุน counterparty limit อัตราส่วนการลงทุนที่คู่สัญญา CRA สถาบันจัดอันดับความน่าเชื ่อถือ (Credit Rating